3 Abstract: 48 SLAMF6 is a homotypic receptor of the Ig-superfamily whose exact role in immune modulation has remained 49 elusive. Its constitutive expression on resting and activated T cells precludes it from being a bona fide 50 exhaustion marker. By breeding Pmel-1 mice with SLAMF6 KO mice, we generated donors for T cells 51 lacking SLAMF6 and expressing a transgenic TCR for gp100-melanoma antigen. Activated Pmel-1xSLAMF6 52 KO CD8 T cells displayed improved polyfunctionality and strong tumor cytolysis. T-bet was the dominant 53 transcription factor in Pmel-1xSLAMF6 KO cells, and upon activation, they acquired an effector-memory 54 phenotype. Blocking LAG-3 improved the function of SLAMF6 deficient T cells even further. Finally, 55
adoptive transfer of Pmel-1xSLAMF6 KO T cells into melanoma-bearing mice resulted in lasting tumor 56
regression in contrast to temporary responses achieved with Pmel-1 T cells. These results support the notion 57 that SLAMF6 is an inhibitory immune receptor whose absence enables powerful CD8 T cells to eradicate 58 tumors. 59
SLAMF6 was shown to inhibit T cell function (Kageyama et al., 2012; Zhao et al., 2012; Bottino et al., 77 2001) . The role of SLAMF6 in healthy T cells expressing normal SAP levels was generally inferred from 78 contextual data and is not yet clear. There are indications that SLAMF6 plays an activating role in double-79 positive thymocytes (Dutta et al., 2013) along with evidence that it plays an inhibitory role in iNKT cells and 80 CD8 T cells (Lu et al., 2019; Eisenberg et al., 2018) . Gene expression profiles of T cell subsets link SLAMF6 81
to the progenitor-exhausted state (Miller et al., 2019) and to the tuning of the critical number of T cells 82 required for proper differentiation (Polonsky et al., 2018) . 83
To elucidate the net function of SLAMF6, we generated a transgenic mouse with the Pmel-1 84 melanoma-specific T-cell receptor (TCR) expressed in CD8 T cells, in which the SLAMF6 gene was knocked 85 out. In this report, we show for the first time that SLAMF6 KO CD8 T cells display improved anti-melanoma 86 activity and prevent melanoma growth more effectively than CD8 T cells with intact and functional SLAMF6. 87
Since SLAMF6 is constitutively expressed on T cells, it acts as an inhibitory checkpoint receptor whose 88 absence allows the eradication of established tumors by CD8 T cells. 89 90 91 92
Results: 93
SLAMF6 is constitutively expressed on T cells and increases upon activation 94
SLAMF6 is an immune receptor constitutively expressed on non-activated and activated T cells 95 (Eisenberg et al., 2018) . The level of SLAMF6 transcription and receptor expression, however, is dynamic, 96
changing with time and activation states. To record SLAMF6 expression in a longitudinal manner, human 97
tumor-infiltrating lymphocytes (TILs) were activated for five days, and SLAMF6 transcript and protein 98 expression were measured ( Figures 1A-C ). After one day of activation, there was an initial decrease in the 99 SLAMF6 transcript that switched to over-expression ( Figure 1C ). From three days after activation onward, 100 SLAMF6 receptor expression consistently increased ( Figures 1A and B ). Interestingly, the increased 101
expression was most pronounced in T cells activated in the absence of IL-2 ( Figure 1D ). A similar pattern was 102 observed for the expression of the murine SLAMF6 receptor on Pmel-1 CD8 T cells ( Figure 1E ). 103
To identify other immune-related genes that may cluster with SLAMF6, longitudinal RNA 104 sequencing data were generated from CD4 T cells from two healthy human donors. Five groups of genes 105
(clusters A-E) were identified ( Figure 1F ). Cluster A represents genes highly expressed in non-activated cells, 106
and downregulated upon activation, such as BCL2 and JAK1. Cluster B represents fast-rising genes 107
undergoing transcription as early as 3-6 hours following activation, but down-regulated after that; genes in 108 this cluster include the activation marker CD69. Clusters C and D include intermediate genes, upregulated 109 after 6 hours (C) or between 12-24 hours (D), and downregulated later. Lastly, cluster E includes late-rising 110 genes, such as LAG3. The SLAMF6 transcript appears in cluster C, rising at 6 hours of activation and staying 111 high after that ( Figure 1G ). Other genes in cluster C are CD44, encoding a glycoprotein that takes part in T 112 cell activation (Huet et al., 1989) , and CD28 and ICOS, which encode co-stimulatory immune receptors 113 (Turka et al., 1990; Dong, Juedes and Temann, 2001) . The increase in the transcription of receptors that are 114
stably expressed at all times may hint at enhanced recruitment and degradation of these receptors during 115 activation, possibly in the immune synapse (Onnis and Baldari, 2019) . 116
117

SLAMF6 expressed in trans by a melanoma target inhibits anti-tumor T cell reactivity 118
Because SLAMF6 is constantly present on T cells, it is difficult to decipher its effect when it acts as a 119 ligand, introduced in trans. To solve this problem, we generated a cell line derived from B16-F10/mhgp100 120 melanoma, over-expressing SLAMF6 (Figure 2A ). Compared to the wild-type cell line, the SLAMF6-121 expressing melanoma cells co-cultured with Pmel-1 CD8 T cells led to decreased IFN-γ secretion by the 122 lymphocytes (Figures 2B and C) . To evaluate the effect of SLAMF6 expression on melanoma rejection in 123 vivo, SLAMF6-expressing melanoma was compared to the parental B16-F10/mhgp100 line, in an adoptive T 124 cell transfer regimen, using activated Pmel-1 CD8 T cells ( Figure 2D ). The B16-F10/mhgp100/SLAMF6 + 125 6 tumors grew more aggressively: on day 23, the mean tumor volume was 380 mm 3 in the SLAMF6-expressing 126 melanomas, compared to 137 mm 3 in the non-modified tumors ( Figure 2E ). 127
These experiments show that trans-activation of SLAMF6 on lymphocytes, which in this system was 128 achieved with the SLAMF6-expressing melanoma, inhibits the melanoma-specific CD8 T cell response and 129 allows rapid tumor growth. 130 131
Establishment of Pmel-1 x SLAMF6 KO mice as a source of SLAMF6-KO antigen-specific lymphocytes 132
To evaluate the role of SLAMF6 in melanoma-cognate T cells, we generated a new mouse strain by 133
breeding Pmel-1 mice with SLAMF6 KO mice. The offspring of this cross represented a new strain, which 134 could serve as a source of CD8 T cells lacking SLAMF6 and expressing the transgenic TCR against the H-135 2D b gp100: 25-33 peptide ( Figure 3A ). Evaluation of the lymphocyte subsets in these mice showed a lower 136 percentage (15%) of CD8 cells in Pmel-1 x SLAMF6 KO mouse spleens compared to Pmel-1 splenocytes 137 (24%) ( Figure 3B and Supplementary Figure 2A ). Despite the smaller percent of CD8 cells in the spleens of 138 the SLAMF6-deficient mice, the ratio of CD8 subpopulations (naïve, effector, effector memory, and central 139 memory) was similar in both mouse strains ( Figure 3C) . 140
In the initial in vitro activation assays, it was already clear that the Pmel-1 x SLAMF6 KO T cells 141
have improved functional capacity. Their proliferative response to peptide stimulation was preserved, which 142 was mandatory to produce ample numbers of CD8 lymphocytes for the adoptive T cell transfer regimen 143
( Figure 3D ). CFSE dilution curves were identical in the two mouse strains, as were the activation-induced cell 144 death (AICD) rates (Supplementary Figures 2B and C) . After three days of activation, the KO mice had higher 145 expression levels of CD25 and CD137 (4-1BB) activation markers ( Figure 3E ). In parallel, higher PD-1 146 expression was detected on day 7 ( Figure 3F ), which in this experimental context was initially taken as an 147
indicator of activation, but was later attributed to SAP deficiency in the SLAMF6 KO lymphocytes (see below 148
in Results and Figures 5A and B ). PD-1 overexpression was also noted by Lu et al. in iNKT cells from SFR 149 KO mice (Lu et al., 2019) . The expression of other SLAM family members and ligands (CD48, LY9, CD244, 150 CD84, CD319) on T cells during activation was similar in Pmel-1 and Pmel-1 x SLAMF6 KO cells 151
(Supplementary Figure 2D) . 152
Lastly, we phenotyped the T cells following 3-day and 7-day activation to assess subset ratios based 153 
Pmel-1 x SLAMF6 KO T cells have a better functional capacity 165
In the previous experiments, the effect of SLAMF6 deletion was evaluated in the activation and 166
proliferation phases. To test if this superior activation also affects anti-tumor immunity, we characterized 167
Pmel-1 x SLAMF6 KO melanoma-specific T cells in the effector phase. 168
Comparing IFN-γ secretion in response to melanoma cells by Pmel-1 versus Pmel-1 x SLAMF6 KO 169 lymphocytes showed that cytokine production by the Pmel-1 x SLAMF6 KO lymphocytes was significantly 170
higher at all effector-to-target ratios (p=0.05, Figures 4A and B and Supplementary Figures 3A and B ). In 171 addition to IFN-γ, higher secretion of GM-CSF and lower levels of IL-10 and IL-13 were measured in the 172
SLAMF6 KO T cells (Figures 4C and D). Since GM-CSF is a strong recruiter of innate immune cells, while 173
IL-10 and IL-13 drive suppressor traits, this secretion profile supports autocrine and paracrine immune 174 activation. mRNA data validated the secretion assays (Supplementary Figure 3C ). Importantly, Pmel-1 x 175 SLAMF6 KO T cells produced higher levels of granzyme B in response to melanoma compared to Pmel-1 T 176 cells, which are already strong killers due to their TCR design ( Figures 4E and F) . These results indicate that 177
in the absence of the SLAMF6 modulatory effect, even strong cytolysis can be further enhanced. 178
To evaluate the anti-tumor activity of Pmel-1 x SLAMF6 KO cells, we assessed adoptive cell transfer 179
(ACT) of 7-day pre-activated gp100:25-33-specific, Pmel-1 or Pmel-1 x SLAMF6 KO CD8 T cells, 180 transferred into mice bearing palpable B16-F10/mhgp100 melanoma in their back skin, followed by a 2-day 181 course of intraperitoneal IL-2 (Figures 4G-J). The spider curves comparing melanoma growth following 182
Pmel-1 versus Pmel-1 x SLAMF6 KO T cell transfer revealed that in the first four weeks post-transfer, tumor 183 growth was inhibited in both groups. However, on week four, tumors treated with Pmel-1 ACT escaped 184 control and grew again in six of the seven animals, whereas mice receiving Pmel-1 x SLAMF6 KO ACT 185 survived longer, and three of the seven treated mice remained tumor-free for over 80 days ( Figure 4H ). 186
Vitiligo was noted in all mice attaining complete response, showing up earlier in the KO group, at the 6 th 187
week, indicating the strength of the response (Supplementary Figure 3D) . 188
In a similar experiment, peptide-activated Pmel-1 CD8 T cells or Pmel-1 x SLAMF6 KO CD8 T cells 189
were transferred into mice bearing 7-day-old tumors. A week later, mice were sacrificed, and spleens, tumors, 190
and tumor-draining lymph nodes were extracted and evaluated for the presence of transferred T cells, using 191 flow cytometry to detect the gp10025-33 tetramer. A higher proportion of gp10025-33 tetramer + cells was found 192 in the draining lymph nodes of mice that had received Pmel-1 x SLAMF6 KO cells ( Figure 4K ) compared to 193 those who had received Pmel-1 cells. Tumors from both groups had a similar density of infiltrating 194 lymphocytes (Supplementary Figure 3E) . 195
In summary, melanoma-specific T cells lacking SLAMF6 showed improved functional capacity both 196 in vitro and in vivo and induced longer-lasting tumor remission with longer tumor control compared to their 197 wild type counterparts. 198 199
Mechanism associated with the inhibitory function of SLAMF6 200
The goal of the next series of experiments was to identify mechanisms underlying the improved 201 effector function of Pmel-1 x SLAMF6 KO lymphocytes. We initially evaluated the level of SAP, the primary 202 adaptor required for SLAMF6 signaling, encoded by the Sh2d1a gene, which was intact in the SLAMF6 KO 203 mice ( Figure 5A ). SAP is a critical adaptor that recruits Fyn kinase to SLAMF6. However, while SAP 204 transcript was found at similar levels in WT and SLAMF6 KO lymphocytes, SAP protein was not detectable 205 in SLAMF6 KO cells ( Figure 5B ). The discrepancy between the transcript and the protein can be explained by 206
rapid degradation of cytoplasmic SAP in its unbound form. SAP protein deficiency also implies that SLAMF6 207 is its major anchor in non-activated CD8 T cells, despite the fact that SAP also mediates the inhibitory activity 208
of PD-1 (Peled et al., 2018) . As shown in Figure 3F , PD-1 expression is more than two-fold increased in 7-209 day activated Pmel-1 x SLAMF6 KO lymphocytes compared to Pmel-1, but, as we have shown, this gap did 210 not affect functionality. Thus, PD-1 overexpression can represent the failure of this receptor to generate a 211 negative feedback loop in over-activated T cells. 212
Next, we measured by flow cytometry the level of phosphorylated ribosomal protein S6 (rpS6), an 213
integrator of important signaling pathways, including PI3K/AKT/mTOR and RAS-ERK ( Figure 5C ). No 214 difference in phosphorylated rpS6 was found in the Pmel-1 x SLAMF6 KO T cells. 215
Therefore, we proceeded to identify transcription regulators whose activity differed between the 216
Pmel-1 cells and the Pmel-1 x SLAMF6 KO cells. The most prominent regulator found was T-bet, which 217 increased more than twofold in activated Pmel-1 x SLAMF6 KO splenocytes, followed by Eomes ( Figure 5D  218 and Supplementary Figure 4) . T-bet was originally described as the key transcription factor defining type 1 T 219 helper (Th) cells; it has since been found to play a major role in the acquisition of effector functions by CD8 T 220 cells (Szabo et al., 2000) . Type 1 inflammatory signals induce T-bet expression (Joshi et al., 2007) , which is 221
in line with the intensive IFN-γ secretion we observed by the Pmel-1 x SLAMF6 KO lymphocytes ( Figure  222 4A). 223
Lastly, the level of immune receptors that mediate exhaustion was recorded during prolonged 224
activation. Five days after the end of a seven-days activation course, Pmel-1 x SLAMF6 KO T cells displayed 225 similar levels of PD-1, CD244 (SLAMF4), and TIM-3 to those in the Pmel-1 cells, but higher expression of 226 LAG-3 ( Figure 5E ). Hypothesizing that LAG-3 represents a compensatory mechanism for the enhanced 227 activation of Pmel-1 x SLAMF6 KO T cells, we used a blocking antibody against LAG-3 in the gp100 228 activation assay. We then measured IFN-γ secretion by activated T cells in response to B16-F10/mhgp100 229 melanoma cells. As expected, blocking LAG-3 on Pmel-1 x SLAMF6 KO lymphocytes increased their 230 cytokine secretion significantly, whereas it did not affect Pmel-1 cells. Overall, knocking out SLAMF6 231 together with LAG-3 blockade resulted in a three-fold increase in IFN-γ production ( Figure 5F) . 232
233
Discussion 234 The aim of this study was to characterize the role of SLAMF6 in CD8 T cells, in the context of an 235
anti-tumor response. The data obtained identify SLAMF6 as a receptor whose absence significantly improves 236
CD8-mediated tumor regression, suggesting that it is an inhibitory checkpoint. 237
Historically, SFRs were studied for their part in X-linked lymphoproliferative disease (XLP), a 238
complex genetic immune dysfunction caused by a SAP mutation. XLP is characterized by a compromised 239
immune response to Epstein-Barr virus (EBV) but also by unrestrained T lymphoblast proliferation, which is 240 not necessarily EBV-induced. Thus, it is unclear whether loss of SAP converts all SFRs into "super-241
inhibitory" receptors or whether, on the contrary, loss of SAP unleashes lymphocytes to proliferate, free from 242
re-stimulation-induced apoptosis (Katz et al., 2014; Kageyama et al., 2012; Zhao et al., 2012; Bottino et al., 243 2001 ). Since SAP is an adaptor common to all SLAM family receptors, the role of each individual receptor 244 was obscured by the shared defect. In this situation, SLAMF6 was considered a receptor with a dual function, 245
depending on the interplay between SAP and SHP-1 and SHP-2, protein phosphatases that bind to tyrosines 246 on the cytoplasmic tail of the receptor (Veillette, 2010; Cannons, Tangye and Schwartzberg, 2011; Detre, 247 Keszei and Romero, 2010). SLAMF6 duality was echoed in data from Veillette that showed differing effects 248 of SLAMF6 on NK cells, enhancing function in the priming phase while suppressing cells in the effector-249
phase . Also, mice lacking individual SFRs exhibit minor immune deviations (Wu and 250 Veillette, 2016; Cannons, Tangye and Schwartzberg, 2011; Veillette, 2010; Calpe et al., 2008) . 251
In the past, we described that targeting SLAMF6 with its soluble ectodomain yielded CD8 T cells that 252
do not need IL-2 supplementation, either in vitro or in vivo, to eradicate established melanoma (Eisenberg et 253 al., 2018) . The beneficial effect of the soluble ectodomain of SLAMF6 prompted us to generate melanoma-254 specific SLAMF6 KO T cells, to characterize the role of the receptor in a solid tumor model. 255
A key finding using the new Pmel-1 x SLAMF6 KO mice described in this manuscript is the absence, 256
in fact, of a dichotomy in SLAMF6 action in effector T cells. On the contrary, knocking-out SLAMF6 in 257 murine antigen-specific CD8 T cells disclosed an unequivocal inhibitory role for the receptor. In its absence, 258
TCR triggering of anti-melanoma CD8 T cells yielded a strong effector phenotype, higher IFN-γ secretion, 259
improved cytolysis, and better outcomes in the adoptive transfer of SLAMF6 KO anti-melanoma CD8 T cells 260
to treat established melanoma. This study identifies SLAMF6 as a powerful inhibitor of anti-tumor immune 261 10 response. The absence of viable SAP in SLAMF6 KO lymphocytes hints that this adaptor takes a major part in 262 the inhibitory effect of SLAMF6. 263
To explore the role of SLAMF6 in T cells without the confounding effects of its function in other cell 264 types, we generated a system in which effector T cells interact with their tumor target based on specific 265 epitope recognition and subsequently generate an immunological synapse. The synapse is a subcellular 266 structure involved in the effect of SLAMF6 and is crucial for its study (Zhao et al., 2012) . However, although 267
we revealed the inhibitory effect of SLAMF6 in the Pmel-1 x SLAMF6 KO mice, the source and 268 configuration of SLAMF6/SLAMF6 homotypic binding in the wild-type situation were still difficult to 269 characterize. We had to generate a SLAMF6-positive B16-F10/mhgp100 melanoma line to measure the effect, 270 or more exactly, the degree of suppression, that SLAMF6 trans-activation has on the capacity of melanoma-271 cognate CD8 T cells to eradicate tumors. As shown (Figure 2E) , the SLAMF6-expressing melanoma 272 suppressed T cell efficacy and consequently had accelerated growth. Thus, SLAMF6 trans-activation is 273 suppressive in the response of CD8 T cells to melanoma. In experiments in which the only sources of 274 SLAMF6 ligation were fraternal T cells, we cannot rule out in cis interactions, i.e., homotypic binding of 275 SLAMF6 molecules on the same cell. 276
The molecular mechanisms underlying the increased functional capacity of Pmel-1 T cells lacking 277
SLAMF6 have common features with XLP, as the absence of SAP implies. But while XLP is a global defect 278 of all cell types of the immune system, and therefore yields mixed derangements, the absence of SLAMF6 is 279 remarkable for the enhanced functionality of CD8 T cells, in which it is the dominating SFR. 280
The transcriptional landscape of SLAMF6 KO T cells was governed by the higher expression of T-281 bet. T-bet is a transcription factor that contributes to Th1 and Th17 phenotypes in CD4 T cells. T-bet is 282 prevalent in cytolytic innate lymphocytes residing in tissues and B cells of mouse strains prone to 283 autoimmunity (Plank et al., 2017; Nixon and Li, 2018) . The increased activity of T-bet in SLAMF6 KO CD8 284
T cells implies that T-bet-regulated pathways may operate in CD8 T cells in the absence of functioning 285 SLAMF6, generating 'type 1' inflammatory traits and high cytotoxicity. The improved production of IFN-γ 286
and GM-CSF, in parallel with reduced IL-10 and IL-13, is also typical for type 1 phenotypes. 287 SLAMF6 should be distinguished from typical exhaustion markers because it is expressed on CD8 T 288 cells, regardless of their state of activation. Yigit et al. suggested that blocking SLAMF6 using an antibody 289
can correct the exhaustion phase of T cells (Yigit et al., 2019) , but we favor the notion that SLAMF6 hampers 290
T cells at any stage, as reflected from the functional superiority of short-term activated Pmel-1 T cells. 291
Depleting SLAMF6 improved CD8 T cells in the short and long-term, as was most evident when the WT 292
Pmel-1 cells induced the regression of melanoma only for a limited period while the Pmel-1 x SLAMF6 KO 293 cells led to lasting responses in mice ( Figure 4H) . 294
While searching for new immunotherapeutic targets, the field of immunotherapy is moving to 295 combination therapies, and to biomarker-based treatment choices, to target the escape mechanisms used by 296 tumors. From the results presented here, we conclude that SLAMF6 is an important checkpoint receptor with 297 a significant inhibitory effect on T cells. The balance between SLAMF6 and LAG-3 and the reciprocal rise of 298 the latter suggests that targeting both may have valuable combinatorial, and perhaps even synergistic, effect. 299
In summary, we have shown that SLAMF6 is a constitutive inhibitory immune receptor; in its 300 absence, CD8 T cells acquire stronger reactivity against tumor cells. The strong effector trait is attributed to a 301 series of T-bet-mediated transcriptional events that drive CD8 T cells to exert strong cytotoxicity and achieve 302 resistant melanoma cells were sub-cloned, and the stably transfected cells were labeled with anti-LY108 Ab 320
and sorted in an ARIA-III sorter. B16-F10/mhgp100 cells transfected with the empty vector were sub-cloned 321 using hygromycin resistance. 322
Tumor-infiltrating lymphocytes (TILs): Fresh tumor specimens taken from resected metastases of melanoma 323 patients were used to release TILs using a microculture assay (Lotem et al., 2002) . Human lymphocytes were 324 cultured in complete medium (CM) consisting of RPMI 1640 supplemented with 10% heat-inactivated human 325 AB serum, 2 mmol/l L-glutamine, 1 mmol/l sodium pyruvate, 1% nonessential amino acids, 25 mmol/l 326 HEPES (pH 7.4), 50 μmol/l 2-ME, and combined antibiotics (all from ThermoFisher Minneapolis, MN, USA). The MART-126-35--reactive clones were further expanded in a second-round of exposure to 30 ng/ml anti-CD3, and 6000 IU/ml rhIL-2 in the presence of 50-fold excess irradiated feeder 341
cells. 342
Antibodies 343
For flow cytometry, cells were labeled with the following reagents: anti-CD16/32 (93) The Pmel-1 mice carry a rearranged TCR specific for a 9-mer epitope (25-32) from murine Pmel 17, 361 overexpressed on transformed melanocytes and homologous to the human melanoma-associated antigen 362
gp100. 363
All experiments were performed with 8-to 12-week-old female mice. 364
Generation of Pmel-1 x SLAMF6 KO mice. Pmel-1 and SLAMF6-/-mice were bred to generate Pmel-1 X 365 SLAMF6-/-mice according to the ethics requirements (Authority for biological and biomedical models, 366
Hebrew University, Jerusalem, Israel). 367
When the mice reached 3 weeks of age, 2 mm of the mouse tail were cut, 200 µl 50 mM NaOH 0.2Mm EDTA 368
were added, and the tails were incubated at 95 o C for 20 min for DNA purification. 200 µl 80 mM TRIS-HCL, 369
pH5, were added to stop the reaction. The DNA purified from the tails was used in PCR reactions for 370 genotyping of mice in the SLAMF6 locus on chromosome 1 (primers adapted from the Jackson laboratories 371 website) and in the Pmel-1 locus on chromosome 2 (Ji et al., 2014) . The identification of the genomic 372 insertion site of the Pmel-1 TCR α and β transgenes was performed by next-generation sequencing. 373
Splenocyte activation 375
Pmel-1 or Pmel-1xSLAMF6-/-mouse splenocytes (2x10 6 /ml) were activated with 1µg/ml of mouse gp10025-33 376 peptide for 6 days with IL-2 30 IU/ml. Fresh medium containing IL-2 was added every other day. GM-CSF secretion. Mouse splenocytes, previously activated for 7 days, were co-cultured (1x10 5 ) overnight at 436 a 1:1 ratio with the indicated target melanoma cells. Conditioned medium was collected, and mouse GM-CSF 437 secretion was measured by ELISA (Biolegend). 438
Immunohistochemistry. For histological analysis, spleen and tumor tissues were cut into 5 µm sections, 439 deparaffinized with xylene, and hydrated with graded ethanol. Endogenous peroxidase was blocked using 3% 440 H2O2 for 5 min. and 0.01M citrate buffer (pH 6.0) was used for antigen retrieval. The samples were cooked in 441 a pressure cooker at maximum power for 13 min and then at 40% power for an additional 15 min, and left to 442 cool for 30 min until they reached room temperature. All slides were then washed in PBS and blocked for 30 443 min with CAS block at room temperature. The tissues were incubated with rabbit anti-CD4 Ab (ab183685) or 444 rabbit anti-CD8 Ab (ab203035) diluted in CAS-Block (1:1000 or 1:250, respectively) overnight at 4°C. The 445
following day, the slides were washed in PBS, incubated with Dako anti-rabbit secondary antibody for 30 min 446
and developed with AEC for 10 min. After several washes in PBS and dH2O, the slides were counterstained 447 with hematoxylin, rinsed in H2O, and covered with fluoromount (ThermoFisher) and a cover-slip. The photos 448
were taken with an Olympus BX50 microscope and Olympus DP73 camera at room temperature. The 449 acquisition software used was CellSens Entry 1.8. 450
Killing assay. Splenocytes were co-cultured for 19h at 37 ºC at a 1:1 ratio with the indicated target melanoma 451 cells. After 16h, Brefeldin A (Biolegend) was added (1:1000). At the end of the incubation, the cells were 452
washed twice with PBS and stained with aCD8 (Biogems, clone 53-6.7) for 30 min at room temperature. 453 SLAMF6. RNA was extracted at the indicated time points. Data normalized to HPRT expression at each time 595 point and to the basal expression level on day 0. One-way ANOVA. **, P < 0.01, ***, P < 0.001. D, SLAMF6 596 expression by flow cytometry in human TIL412 cells activated for 5 days with anti-CD3 or with anti-CD3 597 plus IL-2, at the indicated time points. E, SLAMF6 expression by flow cytometry in Pmel-1 mouse 598 splenocytes activated for 6 days, at the indicated time points. F, Row normalized expression of immune-599 related genes from RNAseq, clustered according to similar expression patterns. CD4+ T cells from two donors 600
were stimulated with anti-CD3 plus anti-CD28 for 72 hours, RNA was extracted and sequenced. Numbers in 601 the top panel indicate hours. G, Magnification of cluster C. SLAMF6 is marked. 602
